Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals (CRNX) has announced new equity grants under its 2021 Employment Inducement Incentive Award Plan. The company's Compensation Committee approved non-qualified stock options to purchase 105,100 shares and 9,950 restricted stock units (RSUs) for 14 new non-executive employees on February 10, 2025.
The stock options were priced at $36.53 per share, matching CRNX's closing price on the Nasdaq Global Select Market. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in equal annual installments over four years. Both grants are contingent on continued employment and were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals (CRNX) ha annunciato nuove concessioni azionarie nell'ambito del suo Piano di Incentivazione per l'Occupazione del 2021. Il Comitato della Compensazione della società ha approvato opzioni su azioni non qualificate per l'acquisto di 105.100 azioni e 9.950 unità azionarie vincolate (RSU) per 14 nuovi dipendenti non esecutivi il 10 febbraio 2025.
Le opzioni azionarie sono state fissate a $36,53 per azione, corrispondente al prezzo di chiusura di CRNX sul Nasdaq Global Select Market. Le opzioni si trasformeranno in diritti nel corso di quattro anni, con il 25% che maturerà dopo un anno e il resto che maturerà mensilmente nei successivi 36 mesi. Le RSU matureranno in rate annuali uguali nel corso di quattro anni. Entrambi i conferimenti sono subordinati al mantenimento dell'impiego e sono stati effettuati in conformità alla Regola di Quotazione del Nasdaq 5635(c)(4).
Crinetics Pharmaceuticals (CRNX) ha anunciado nuevas concesiones de acciones bajo su Plan de Incentivo por Empleo 2021. El Comité de Compensación de la empresa aprobó opciones sobre acciones no calificadas para la compra de 105.100 acciones y 9.950 unidades de acciones restringidas (RSUs) para 14 nuevos empleados no ejecutivos el 10 de febrero de 2025.
Las opciones sobre acciones se fijaron en $36.53 por acción, coincidiendo con el precio de cierre de CRNX en el Nasdaq Global Select Market. Las opciones se consolidarán durante cuatro años, con un 25% consolidándose después de un año y el resto consolidándose mensualmente durante los siguientes 36 meses. Las RSUs se consolidarán en cuotas anuales iguales durante cuatro años. Ambas concesiones están sujetas a la continuidad del empleo y se realizaron de acuerdo con la Regla de Cotización Nasda 5635(c)(4).
Crinetics Pharmaceuticals (CRNX)는 2021년 고용 유인 인센티브 수여 계획에 따라 새로운 주식 부여를 발표했습니다. 회사의 보상 위원회는 2025년 2월 10일 14명의 비임원 신규 직원에게 105,100주의 비자격 주식 옵션과 9,950주의 제한 주식 유닛(RSU)을 구매할 수 있도록 승인했습니다.
주식 옵션의 가격은 $36.53 주당로, CRNX의 나스닥 글로벌 선택 시장에서의 종가와 일치합니다. 옵션은 4년 동안 발생하며, 1년 후 25%가 발생하고 나머지는 36개월 동안 매월 발생합니다. RSU는 4년에 걸쳐 균등한 연간 할부로 발생합니다. 두 가지 부여는 고용 지속성에 따라 달라지며 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Crinetics Pharmaceuticals (CRNX) a annoncé de nouvelles attributions d'actions dans le cadre de son Plan d'Incentivation à l'Emploi 2021. Le Comité de Rémunération de l'entreprise a approuvé des options d'achat d'actions non qualifiées pour l'acquisition de 105.100 actions et 9.950 unités d'actions restreintes (RSUs) pour 14 nouveaux employés non exécutifs le 10 février 2025.
Les options d'achat d'actions ont été fixées à 36,53 $ par action, correspondant au prix de clôture de CRNX sur le Nasdaq Global Select Market. Les options seront acquises sur une période de quatre ans, avec 25 % acquises après un an et le reste acquis mensuellement pendant 36 mois. Les RSUs seront acquises par tranches annuelles égales sur quatre ans. Les deux attributions sont conditionnées à la poursuite de l'emploi et ont été effectuées conformément à la Règle de Cotation 5635(c)(4) du Nasdaq.
Crinetics Pharmaceuticals (CRNX) hat neue Aktienvergaben im Rahmen seines 2021 Employment Inducement Incentive Award Plans angekündigt. Der Vergütungsausschuss des Unternehmens genehmigte nicht qualifizierte Aktienoptionen zum Kauf von 105.100 Aktien und 9.950 Restricted Stock Units (RSUs) für 14 neue nicht-executive Mitarbeiter am 10. Februar 2025.
Die Aktienoptionen wurden zu $36,53 pro Aktie festgelegt, was dem Schlusskurs von CRNX am Nasdaq Global Select Market entspricht. Die Optionen werden über vier Jahre hinweg vested, wobei 25% nach einem Jahr und der Rest monatlich über 36 Monate vesten. Die RSUs werden in gleichen jährlichen Raten über vier Jahre hinweg aktiviert. Beide Gewährungen sind an die Fortdauer des Arbeitsverhältnisses gebunden und wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) vorgenommen.
- Company demonstrates ability to attract new talent with equity compensation
- Stock options granted at market price ($36.53), showing fair compensation practices
- Potential future dilution from 115,050 new shares (options and RSUs combined)
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on February 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 105,100 shares of its common stock and granted an aggregate of 9,950 restricted stock unit (“RSU”) awards to 14 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2021 Inducement Plan is used exclusively for granting equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, first-in-class, oral ACTH antagonist, that is currently in development for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 450-6464
FAQ
How many shares were granted in CRNX's February 2025 inducement grants?
What is the exercise price for CRNX's February 2025 stock option grants?
What is the vesting schedule for CRNX's February 2025 stock option grants?
How do the RSUs vest in CRNX's February 2025 inducement grants?
How many new employees received CRNX's February 2025 inducement grants?
